Aldesleukin shows promise.
D019380:Anti-HIV Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D017322:Clinical Trials, Phase II as Topic; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D007376:Interleukin-2 / Q000031:analogs & derivatives* / Q000037:antagonists & inhibitors* / Q000494:pharmacology / Q000627:therapeutic use; D015337:Multicenter Studies as Topic; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins / Q000494:pharmacology / Q000627:therapeutic use; D014481:United States; D019562:Viral Load
D019380:Anti-HIV Agents; D007376:Interleukin-2; D011994:Recombinant Proteins; C082598:aldesleukin